Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandwich Combination Therapy (HT-102 + FD-001) for HBV/HCC
NCT07088133Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
Open-label, single-arm trial of HT-102 and FD-001 in hepatitis B (HBV), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Positive convention rate of HBsAb at 49 weeks and Hepatocellular Carcinoma recurrence rate at 49 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
HT-102FD-001
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07088133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088133.